Milestone Pharmaceuticals to present new analysis from trials for PSVT

Milestone Pharmaceuticals (MIST) announced that new data analyses surrounding its lead investigational product for the management of paroxysmal supraventricular tachycardia, PSVT, etripamil nasal spray, consistently showed efficacy and a favorable safety profile across multiple studies comprising the global development program. The poster, “Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia Across Multiple Clinical Trials,” will be presented on Monday, November 10 at the American Heart Association Scientific Sessions 2025, in New Orleans, La. Key Findings: Analysis of data from 622 unique enrolled patients across multiple trials showed consistent efficacy of etripamil across multiple study phases, types of trial design, and geographic regions, with etripamil treatment showing similarly greater conversion rates for symptomatic PSVT episodes compared with placebo arms. Across studies, the median time to conversion in patients self-administering etripamil was 18.5 minutes. The Kaplan-Meier estimate, from the pooled data for conversion of PSVT to sinus rhythm by 30 minutes of drug administration, was 59.6%. Safety data from over 1,050 etripamil-treated patients were favorable, consistently shown. The low rate of test-dose failures among over 1,100 patients administered etripamil in SR further indicates the consistent tolerability of etripamil.